KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Divestments: 2023-2025

Historic Divestments for Royalty Pharma (RPRX) over the last 3 years, with Sep 2025 value amounting to $905,000.

  • Royalty Pharma's Divestments fell 92.12% to $905,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $103.4 million, marking a year-over-year increase of 312.70%. This contributed to the annual value of $23.6 million for FY2024, which is 46.13% down from last year.
  • Royalty Pharma's Divestments amounted to $905,000 in Q3 2025, which was down 98.56% from $63.0 million recorded in Q2 2025.
  • Royalty Pharma's Divestments' 5-year high stood at $63.0 million during Q2 2025, with a 5-year trough of $905,000 in Q3 2025.
  • In the last 3 years, Royalty Pharma's Divestments had a median value of $4.8 million in 2023 and averaged $16.8 million.
  • Data for Royalty Pharma's Divestments shows a peak YoY increase of 1,497.46% (in 2025) and a maximum YoY decrease of 92.12% (in 2025) over the last 5 years.
  • Royalty Pharma's Divestments (Quarterly) stood at $4.7 million in 2023, then tumbled by 30.34% to $3.2 million in 2024, then crashed by 92.12% to $905,000 in 2025.
  • Its Divestments stands at $905,000 for Q3 2025, versus $63.0 million for Q2 2025 and $36.3 million for Q1 2025.